SCHEMBL6798402

SCHEMBL6798402

CCOC(=O)c1cc2c(C(F)(F)F)cc(CCI)cc2n1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.37
ALOX5 P09917 2/20 0.37
ALDH1A1 P00352 5/20 0.36
HPGD P15428 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
LDHA P00338 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
PGR P06401 1/20 0.33
AR P10275 1/20 0.33
KMT2A Q03164 1/20 0.33
MAPT P10636 2/20 0.33
MAPK1 P28482 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6798912 0.90 KDM4E (0.37) KDM4EALOX5ALDH1A1HPGDCYP1A2
SCHEMBL6798023 0.87 ALDH1A1 (0.39) KDM4EALOX5ALDH1A1HPGDCYP1A2
SCHEMBL6797139 0.86 ALDH1A1 (0.40) KDM4EALOX5ALDH1A1HPGDCYP1A2
SCHEMBL6798204 0.86 KDM4E (0.35) KDM4EALOX5ALDH1A1HPGDCYP1A2
SCHEMBL6796807 0.84 KDM4E (0.34) KDM4EALOX5ALDH1A1HPGDCYP1A2
SCHEMBL6797518 0.83 KDM4E (0.40) KDM4EALOX5ALDH1A1HPGDCYP1A2
SCHEMBL6799070 0.83 POLB (0.41) KDM4EALOX5ALDH1A1HPGDCYP1A2
SCHEMBL6797977 0.82 ALOX5 (0.44) KDM4EALOX5ALDH1A1HPGDCYP1A2
SCHEMBL6797140 0.81 ALOX5 (0.37) KDM4EALOX5ALDH1A1HPGDCYP1A2
SCHEMBL6802816 0.79 KDM4E (0.38) KDM4EALOX5ALDH1A1HPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734205-B2 SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2004-05-11 US disclosed
US-20030018056-A1 Substituted guanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2003-01-23 US disclosed
EP-1238971-A1 SUBSTITUTED GUANIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018056-A1 Substituted guanidine derivatives SLC28A1, SLC7A1, ABCB11 KDM4E 1068/4885ALOX5 2297/4885ALDH1A1 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.